549 related articles for article (PubMed ID: 24366912)
1. Lactate dehydrogenase A silencing in IDH mutant gliomas.
Chesnelong C; Chaumeil MM; Blough MD; Al-Najjar M; Stechishin OD; Chan JA; Pieper RO; Ronen SM; Weiss S; Luchman HA; Cairncross JG
Neuro Oncol; 2014 May; 16(5):686-95. PubMed ID: 24366912
[TBL] [Abstract][Full Text] [Related]
2. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
[TBL] [Abstract][Full Text] [Related]
3. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
5. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
[TBL] [Abstract][Full Text] [Related]
6. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
Yao J; Chakhoyan A; Nathanson DA; Yong WH; Salamon N; Raymond C; Mareninov S; Lai A; Nghiemphu PL; Prins RM; Pope WB; Everson RG; Liau LM; Cloughesy TF; Ellingson BM
Neuro Oncol; 2019 Sep; 21(9):1184-1196. PubMed ID: 31066901
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
Mo H; Magaki S; Deisch JK; Raghavan R
J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
11. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
[TBL] [Abstract][Full Text] [Related]
13. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Gerardo Valadez J; Grover VK; Carter MD; Calcutt MW; Abiria SA; Lundberg CJ; Williams TV; Cooper MK
Cancer Lett; 2013 Jan; 328(2):297-306. PubMed ID: 23063752
[TBL] [Abstract][Full Text] [Related]
14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
16. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
17. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
20. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]